abstract |
Disclosed herein are compounds that inhibit dual leucine zipper kinase (DLK) kinase activity (MAP3K12), pharmaceutical compositions, and methods of treating DLK-mediated diseases, such as neurological diseases resulting from traumatic injury. to the central nervous system and neurons of the peripheral nervous system (eg, stroke, traumatic brain injury, spinal cord injury), or resulting from a chronic neurodegenerative condition (eg, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy disease and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy and related disorders) and of cognitive disorders caused by inte Pharmacological intervention (eg, chemotherapy-induced cognitive disorder, also known as chemobrain). |